COMPOSITIONS AND METHODS TO BLOCK AND BIND CXCR4 TO MODULATE CELLULAR FUNCTION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 8, 2022
app pub date -
Jul 13, 2020
filing date -
Jul 12, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided are composition comprising antibodies directed to the N-terminal domain of CXCR4. The antibody may be a scFv and can be fused to a RNA binding peptide. The fusion protein can be complexed to RNAi, such as micro RNA. The complexes can be used for targeting delivery of RNAi molecules to CXCR4 expressing cancer cells, as well as inhibiting the binding of CXCR4 to CXCL12.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully